Top 20 Cancer Therapy Brands Sales of targeted therapies overtake cytotoxics in 2006

ABOUT DATAMONITOR HEALTHCARE
2

About the Oncology pharmaceutical analysis team
2

CHAPTER 1 EXECUTIVE SUMMARY
3

Scope of the analysis
3

Datamonitor insight into the cancer market
4

Related reports
6

Upcoming reports
6

CHAPTER 2 MARKET OVERVIEW AND DYNAMICS
8

The Top 20 cancer therapy brands - 2006
8

The current market situation
11

The Top 20 cancer therapy brands - 2016
14

Sales by class
16

Molecular targeted therapies set to dominate over the forecast period
16

US
17

Japan
19

France
21

Germany
23

Italy
25

Spain
27

UK
29

5EU
31

Seven major markets
33

Sales by country
35

Other countries slowly catching up with the lucrative US market
35

Brands by class and mode of action
37

Cytotoxic therapies still make up the majority of the forecasted cancer therapy brands
37

Brands by indication
39

Breast cancer drugs strongly dominate among the forecasted cancer therapy brands
39

Brands by company
41

AstraZeneca and Roche are behind the highest number of forecasted cancer therapy brands
41

Brands by event
43

Avastin set to experience the highest number of different events over the forecast period
43

Brands by compound annual growth rate
45

Molecular targeted therapies are driving the positive CAGR for the forecasted cancer therapy brands
45

CHAPTER 3 MARKET DEFINITION
49

Market definition for this report
49

Cytotoxic therapies
50

L1A - Alkylating agents
50

L1B - Antimetabolites
50

L1C - Vinca alkaloids and other plant-derived products
50

L1D - Antineoplastic antibiotics
50

L1X2 - Platinum compounds
51

Antihormonal therapies
51

L2A3 - Luteinizing hormone-releasing hormone analogs
51

L2B1 - Anti-estrogens
51

L2B2 - Anti-androgens
52

L2B3 - Aromatase inhibitors
52

Molecular targeted therapies
52

L1X3 - Antineoplastic monoclonal antibodies
52

L1X9 - All other antineoplastics
53

CHAPTER 4 COUNTRY MARKET ASSESSMENTS
54

Current and future opportunities and threats in the cancer market
54

Global opportunities and threats
54

Opportunities
54

Threats
59

US: opportunities and threats
64

Opportunities
64

Threats
66

Japan: opportunities and threats
68

Opportunities
68

Threats
69

5EU: opportunities and threats
71

Opportunities
71

Threats
73

France: opportunities and threats
75

Opportunities
75

Threats
76

Germany: opportunities and threats
77

Opportunities
77

Threats
78

Italy: opportunities and threats
79

Opportunities
79

Threats
80

Spain: opportunities and threats
82

Opportunities
82

Threats
83

UK: opportunities and threats
84

Opportunities
84

Threats
84

Summary of environmental issues affecting the cancer market size
87

CHAPTER 5 FORECAST ANALYSIS
89

Country-specific assumptions and events
89

Effect of Medicare Modernization Act in the US
89

Biennial price cuts in Japan
89

Generic erosion assumptions
89

Product-specific assumptions and events
90

Cytotoxic therapies
90

Abraxane (ABX-007; Abraxis BioScience/AstraZeneca)
90

Alimta (Pemetrexed; Eli Lilly)
92

Camptosar/Campto (Irinotecan; Pfizer/Yakult/Daiichi)
94

Doxil/Caelyx (Pegylated liposomal doxorubicin; Johnson & Johnson/Schering-Plough)
96

Ellence/Farmorubicin (Epirubicin; Pfizer)
98

Eloxatin (Oxaliplatin; Sanofi-Aventis)
100

Furtulon (Doxifluridine; Roche/Chugai)
103

Gemzar (Gemcitabine; Eli Lilly)
104

Navelbine (Vinorelbine; Pierre Fabre/GlaxoSmithKline)
106

Paraplatin (Carboplatin; Bristol-Myers Squibb)
107

Taxol (Paclitaxel; Bristol-Myers Squibb)
108

Taxotere (Docetaxel; Sanofi-Aventis)
110

Temodar/Temodal (Temozolomide; Schering-Plough)
113

TS-1 (Tegafur, gimeracil & oteracil; Taiho Pharmaceuticals/Sanofi-Aventis)
115

UFT (Tegafur & uracil; Taiho Pharmaceuticals)
117

Xeloda (Capecitabine; Roche)
119

Antihormonal therapies
121

Arimidex (Anastrozole; AstraZeneca)
121

Aromasin (Exemestane; Pfizer)
123

Casodex (Bicalutamide; AstraZeneca)
125

Femara (Letrozole; Novartis)
127

Lupron (Leuprorelin; Takeda/TAP/Abbott/Wyeth)
129

Nolvadex (Tamoxifen; AstraZeneca)
130

Zoladex (Goserelin; AstraZeneca)
133

Molecular targeted therapies
134

Avastin (Bevacizumab; Genentech/Roche)
134

Erbitux (Cetuximab; ImClone/Bristol-Myers Squibb/Merck Serono)
137

Gleevec/Glivec (Imatinib; Novartis)
141

Herceptin (Trastuzumab; Genentech/Roche)
144

Iressa (Gefitinib; AstraZeneca)
147

Nexavar (Sorafenib; Onyx Pharmaceuticals/Bayer Schering)
149

Rituxan/MabThera (Rituximab; Biogen Idec/Genentech/Roche)
153

Sutent (Sunitinib; Pfizer)
155

Tarceva (Erlotinib; OSI Pharmaceuticals/Genentech/Roche)
157

Tykerb (Lapatinib; GlaxoSmithKline)
159

Vectibix (Panitumumab; Amgen)
161

Velcade (Bortezomib; Ortho Biotech/Millennium Pharmaceuticals)
165

Data definitions, limitations and assumptions
167

Standard units
167

Japanese market data
167

Derivation of sales forecasts and pricing trends
167

Forecasts
168

Forecast methodology
168

BIBLIOGRAPHY
169

APPENDIX A - MARKET DATA AND MAJOR BRAND KEY FACTS
177

Cytotoxic therapies market data
177

Antihormonal therapies market data
185

Molecular targeted therapies market data
189

APPENDIX B - MARKET FORECAST DATA
195

US forecasts
195

Japan forecasts
197

France forecasts
199

Germany forecasts
201

Italy forecasts
203

Spain forecasts
205

UK forecasts
207

5EU forecasts
209

Seven major market forecasts
211

APPENDIX C
213

Report methodology
213

About Datamonitor
213

About Datamonitor Healthcare
213

Disclaimer
215

List of Tables

Table 1: Top 20 cancer therapy brands in the US, Japan, Germany and France, 2006
9

Table 2: Top 20 cancer therapy brands in Italy, Spain, the UK, collective 5EU and collective seven major markets, 2006
10

Table 3: Newly marketed drugs included in the Top 20 cancer therapy brands, 2006-2017
11

Table 4: Seven major market sales of Top 20 cancer therapy brands by drug class, 2006
11

Table 5: Molecular targeted therapies included in the Top 20 cancer therapy brands, 2006
12

Table 6: Cytotoxic therapies included in the Top 20 cancer therapy brands, 2006
13

Table 7: Antihormonal therapies included in the Top 20 cancer therapy brands, 2006
14

Table 8: Top 20 cancer therapy brands in the US, Japan, Germany and France, 2016
15

Table 9: Top 20 cancer therapy brands in Italy, Spain, the UK, collective 5EU and collective seven major markets, 2006
16

Table 10: Forecasted cancer therapy brands by number of different events, 2007-2016
43

Table 11: Definition of the cancer market, 2007
49

Table 12: Abraxane: key facts
90

Table 13: Alimta: key facts
92

Table 14: Camptosar: key facts
94

Table 15: Doxil: key facts
96

Table 16: Ellence: key facts
98

Table 17: Eloxatin: key facts
100

Table 18: Furtulon: key facts
103

Table 19: Gemzar: key facts
104

Table 20: Navelbine: key facts
106

Table 21: Paraplatin: key facts
107

Table 22: Taxol: key facts
108

Table 23: Taxotere: key facts
110

Table 24: Market share of Taxotere, 2005
111

Table 25: Temodar: key facts
113

Table 26: TS-1: key facts
115

Table 27: UFT: key facts
117

Table 28: Xeloda: key facts
119

Table 29: Arimidex: key facts
121

Table 30: Aromasin: key facts
123

Table 31: Casodex: key facts
125

Table 32: Femara: key facts
127

Table 33: Lupron: key facts
129

Table 34: Nolvadex: key facts
130

Table 35: Zoladex: key facts
133

Table 36: Avastin: key facts
134

Table 37: Erbitux: key facts
137

Table 38: Gleevec: key facts
141

Table 39: Herceptin: key facts
144

Table 40: Iressa: key facts
147

Table 41: Nexavar: key facts
149

Table 42: Rituxan: key facts
153

Table 43: Approved indications for Rituxan in the US and EU, 2006
154

Table 44: Sutent: key facts
155

Table 45: Tarceva: key facts
157

Table 46: Tykerb: key facts
159

Table 47: Vectibix: key facts
161

Table 48: Velcade: key facts
165

Table 49: Abraxane: key facts
177

Table 50: Alimta: key facts
177

Table 51: Camptosar: key facts
178

Table 52: Doxil: key facts
178

Table 53: Ellence: key facts
179

Table 54: Eloxatin: key facts
179

Table 55: Furtulon: key facts
180

Table 56: Gemzar: key facts
180

Table 57: Navelbine: key facts
181

Table 58: Paraplatin: key facts
181

Table 59: Taxol: key facts
182

Table 60: Taxotere: key facts
182

Table 61: Temodar: key facts
183

Table 62: TS-1: key facts
183

Table 63: UFT: key facts
184

Table 64: Xeloda: key facts
184

Table 65: Arimidex: key facts
185

Table 66: Aromasin: key facts
185

Table 67: Casodex: key facts
186

Table 68: Femara: key facts
186

Table 69: Lupron: key facts
187

Table 70: Nolvadex: key facts
187

Table 71: Zoladex: key facts
188

Table 72: Avastin: key facts
189

Table 73: Erbitux: key facts
189

Table 74: Gleevec: key facts
190

Table 75: Herceptin: key facts
190

Table 76: Iressa: key facts
191

Table 77: Nexavar: key facts
191

Table 78: Rituxan: key facts
192

Table 79: Sutent: key facts
192

Table 80: Tarceva: key facts
193

Table 81: Tykerb: key facts
193

Table 82: Vectibix: key facts
194

Table 83: Velcade: key facts
194

Table 84: US forecasts for the Top 20 cancer therapy brands ($m), 2006-2016 (1 of 2)
195

Table 85: US forecasts for the Top 20 cancer therapy brands ($m), 2006-2016 (2 of 2)
196

Table 86: Japan forecasts for the Top 20 cancer therapy brands ($m), 2006-2016 (1 of 2)
197

Table 87: Japan forecasts for the Top 20 cancer therapy brands($m), 2006-2016 (2 of 2)
198

Table 88: France forecasts for the Top 20 cancer therapy brands ($m), 2006-2016 (1 of 2)
199

Table 89: France forecasts for the Top 20 cancer therapy brands ($m), 2006-2016 (2 of 2)
200

Table 90: Germany forecasts for the Top 20 cancer therapy brands ($m), 2006-2016 (1 of 2)
201

Table 91: Germany forecasts for the Top 20 cancer therapy brands ($m), 2006-2016 (2 of 2)
202

Table 92: Italy forecasts for the Top 20 cancer therapy brands ($m), 2006-2016 (1 of 2)
203

Table 93: Italy forecasts for the Top 20 cancer therapy brands ($m), 2006-2016 (2 of 2)
204

Table 94: Spain forecasts for the Top 20 cancer therapy brands ($m), 2006-2016 (1 of 2)
205

Table 95: Spain forecasts for the Top 20 cancer therapy brands ($m), 2006-2016 (2 of 2)
206

Table 96: UK forecasts for the Top 20 cancer therapy brands ($m), 2006-2016 (1 of 2)
207

Table 97: UK forecasts for the Top 20 cancer therapy brands ($m), 2006-2016 (2 of 2)
208

Table 98: 5EU forecasts for the Top 20 cancer therapy brands ($m), 2006-2016 (1 of 2)
209

Table 99: 5EU forecasts for the Top 20 cancer therapy brands ($m), 2006-2016
210

Table 100: Seven major market forecasts for the Top 20 cancer therapy brands ($m), 2006-2016 (1 of 2)
211

Table 101: Seven major market forecasts for the Top 20 cancer therapy brands ($m), 2006-2016 (2 of 2)
212

List of Figures

Figure 1: US Top 20 cancer therapy brand sales by class: 2006
17

Figure 2: US Top 20 cancer therapy brand sales by class: 2016
18

Figure 3: Japan Top 20 cancer therapy brand sales by class: 2006
19

Figure 4: Japan Top 20 cancer therapy brand sales by class: 2016
20

Figure 5: France Top 20 cancer therapy brand sales by class: 2006
21

Figure 6: France Top 20 cancer therapy brand sales by class: 2016
22

Figure 7: Germany Top 20 cancer therapy brand sales by class: 2006
23

Figure 8: Germany Top 20 cancer therapy brand sales by class: 2016
24

Figure 9: Italy Top 20 cancer therapy brand sales by class: 2006
25

Figure 10: Italy Top 20 cancer therapy brand sales by class: 2016
26

Figure 11: Spain Top 20 cancer therapy brand sales by class: 2006
27

Figure 12: Spain Top 20 cancer therapy brand sales by class: 2016
28

Figure 13: UK Top 20 cancer therapy brand sales by class: 2006
29

Figure 14: UK Top 20 cancer therapy brand sales by class: 2016
30

Figure 15: 5EU Top 20 cancer therapy brand sales by class: 2006
31

Figure 16: 5EU Top 20 cancer therapy brand sales by class: 2016
32

Figure 17: Seven major markets Top 20 cancer therapy brand sales by class: 2006
33

Figure 18: Seven major markets Top 20 cancer therapy brand sales by class: 2016
34

Figure 19: Top 20 cancer therapy brand sales by country: 2006
35

Figure 20: Top 20 cancer therapy brand sales by country: 2016
36

Figure 21: Forecasted cancer therapy brands by class
37

Figure 22: Forecasted cancer therapy brands by mode of action
38

Figure 23: Forecasted cancer therapy brands by indication
40

Figure 24: Forecasted cancer therapy brands by company
42

Figure 25: Forecasted cancer therapy brands by number of different events, 2007-2016
44

Figure 26: Forecasted cancer therapy brands by CAGR, 2006-2016
45

Figure 27: Molecular targeted therapy brands by CAGR, 2006-2016
46

Figure 28: Cytotoxic therapy brands by CAGR, 2006-2016
47

Figure 29: Antihormonal therapy brands by CAGR, 2006-2016
48

Figure 30: Seven market population aged 60 and over, 2000-2050
54

Figure 31: Forecast incidence of cancer across the seven major pharmaceutical markets, 2001-2015
55

Figure 32: Global oncology sales ($m), 2002-2011
56

Figure 33: Summary of global opportunities and threats affecting the cancer market, 2007
87

Figure 34: Summary of regional opportunities and threats affecting the cancer market, 2007
88